Introduction: Annual outbreak of Lassa Fever (LF) has been reported in Ondo State over the years. We analyzed LF surveillance data from January 2014 to December 2019 to describe the epidemiological pattern of the outb...Introduction: Annual outbreak of Lassa Fever (LF) has been reported in Ondo State over the years. We analyzed LF surveillance data from January 2014 to December 2019 to describe the epidemiological pattern of the outbreak. Method: Lassa fever dataset from January 2014 to December 2019 was obtained from the State Ministry of Health. Variables analyzed include date of onset of symptom, age, gender, place (Local Government Area, LGA) and outcome of laboratory test. Data were summarized using frequencies, proportions, chart and maps. Results: From January 2014 and December 2019, 2141 suspected LF cases were reported. Of these, 551 cases were laboratory confirmed with 134 deaths recorded. The LF cases (suspected vs. confirmed) reported increased in 2016 (73 vs. 19), 2017 (207 vs. 76), 2018 (452 vs. 159) and 2019 (856 vs. 285) respectively. Most of the confirmed cases (89.5%) were ≥15 years while more than half (53.7%) were males. Prior to 2016, only two LGAs (Owo and Ose) recorded continued transmission of the disease. However, between 2016 and 2019, the disease had spread to 8 neighboring LGAs (P < 0.001) with the CFR declining from 67% in 2015 to 20% in 2019. Conclusion: We found an unusual increase in the suspected LF cases reported between January 2016 and December 2019 with a corresponding increase in the confirmed cases and high annual case fatality rates. Hence, we recommend intensified surveillance activities to enhance timely reporting of cases and laboratory confirmation to ensure early commencement of treatment to reduce the case fatality rate.展开更多
Introduction: Hematological malignancies (HM) are relatively frequent nosological entities within the structure of morbidity by malignant tumors, exhibiting a severe evolution, restrained prognosis and negative socio-...Introduction: Hematological malignancies (HM) are relatively frequent nosological entities within the structure of morbidity by malignant tumors, exhibiting a severe evolution, restrained prognosis and negative socio-economic impact in the advanced stages and phases. Objective: The objective of the study was to identify the epidemiological patterns, and to evaluate the epidemiological trends and disease burden issues of HM in the Republic of Moldova and worldwide. Materials and Methods: The following research methods were used: epidemiological, descriptive statistics, clinico-analytic. The diagnosis was proved in all cases by histopathological, cytological, cytogenetic, molecular and immunophenotyping examinations. The qualitative type researches were performed and enriched by the narrative synthesis of the data. From the specialized international bibliographic sources and official statistics concerning HM. The narrative review of the reference sources was fulfilled in the form of a synthesis. Results: The number of newly diagnosed and followed-up patients with HM at the Institute of Oncology in 2016, 2017, 2018, 2019, 2020 and 2021 amounted respectively to 725, 802, 613, 628, 536 and 528, the incidence (new cases per 100,000 population) being 17.6, 19.5, 14.9, 17.7, 15.1 and 20.3. In 2021 HM constituted 6.2% of all newly-diagnosed cases with malignant tumors in the Republic of Moldova. In the same year Hodgkin lymphoma was diagnosed in 10.04% of cases, non-Hodgkin’s lymphomas—in 31.63%, multiple myeloma and plasma cells neoplasms—in 7.77%, lymphoid leukemias—in 17.42%, myeloid leukemias—in 12.31%, monocytic leukemias—in 0.95%, and other leukemias—in 16.29%. In 2019 the male rate was 51.5%, and the female rate—48.5%. Within 2 years males were 266 (50.4%), females—262 (49.6%). The age of 50 - 79 years prevailed in both genders (males—65%, females—72.5%). The children constituted 4.0% of the newly diagnosed cases, 4.8% of those under the follow-up at the end of the year 2019 and 6.4% of the newly diagnosed cases in 2021. The disease span from the onset to diagnosis ranged between 1 - 24 months and constituted on average 5.63 months, without a significant difference as compared to 2019 (5.76 months). The incidence of HM in Western countries is 14 - 19 new cases per 100,000 population (4% of all cases with malignant tumors). The incidence of non-Hodgkin’s lymphomas increased by 45% between 2006 and 2016, from 319,078 to 461,000 cases. Between 2006 and 2016, the incidence of leukemias increased by 26%, from 37,000,000 to 467,000 cases. Conclusions: The epidemiological study revealed slightly lower morbidity by HM in the Republic of Moldova as compared to the West European countries mainly due to the migration of a workable population. The patients with malignant lymphomas, male gender and age categories of 50 - 79 years proved to be commonly registered epidemiological patterns. The narrative analysis of the literature revealed that patients with HM may experience a considerable disease burden with a negative impact on their employment status, working productivity and annual household income.展开更多
There were only 75 confirmed cases of coronavirus disease 2019(COVID-19)reported in Libya by the National Center for Disease Control during the first two months following the first confirmed case on 24 March 2020.Howe...There were only 75 confirmed cases of coronavirus disease 2019(COVID-19)reported in Libya by the National Center for Disease Control during the first two months following the first confirmed case on 24 March 2020.However,there was dramatic increase in positive cases from June to now;as of 19 November 2020,approximately 357940 samples have been tested by reverse transcription polymerase chain reaction,and the results have revealed a total number of 76808 confirmed cases,47587 recovered cases and 1068 deaths.The case fatality ratio was estimated to be 1.40%,and the mortality rate was estimated to be 15.90 in 100000 people.The epidemiological situation markedly changed from mid-July to the beginning of August,and the country proceeded to the cluster phase.COVID-19 has spread in almost all Libyan cities,and this reflects the high transmission rate of the virus at the regional level with the highest positivity rates,at an average of 14.54%.Apparently,there is an underestimation of the actual number of COVID-19 cases due to the low testing capacity.Consequently,the Libyan health authority needs to initiate a large-scale case-screening process and enforce testing capacities and contact testing within the time frame,which is not an easy task.Advisably,the Libyan health authority should improve the public health capacities and conduct strict hygienic measures among the societies and vaccinate as many people against COVID-19 to minimize both the case fatality ratio and socio-economic impacts of the pandemic in Libya.展开更多
文摘Introduction: Annual outbreak of Lassa Fever (LF) has been reported in Ondo State over the years. We analyzed LF surveillance data from January 2014 to December 2019 to describe the epidemiological pattern of the outbreak. Method: Lassa fever dataset from January 2014 to December 2019 was obtained from the State Ministry of Health. Variables analyzed include date of onset of symptom, age, gender, place (Local Government Area, LGA) and outcome of laboratory test. Data were summarized using frequencies, proportions, chart and maps. Results: From January 2014 and December 2019, 2141 suspected LF cases were reported. Of these, 551 cases were laboratory confirmed with 134 deaths recorded. The LF cases (suspected vs. confirmed) reported increased in 2016 (73 vs. 19), 2017 (207 vs. 76), 2018 (452 vs. 159) and 2019 (856 vs. 285) respectively. Most of the confirmed cases (89.5%) were ≥15 years while more than half (53.7%) were males. Prior to 2016, only two LGAs (Owo and Ose) recorded continued transmission of the disease. However, between 2016 and 2019, the disease had spread to 8 neighboring LGAs (P < 0.001) with the CFR declining from 67% in 2015 to 20% in 2019. Conclusion: We found an unusual increase in the suspected LF cases reported between January 2016 and December 2019 with a corresponding increase in the confirmed cases and high annual case fatality rates. Hence, we recommend intensified surveillance activities to enhance timely reporting of cases and laboratory confirmation to ensure early commencement of treatment to reduce the case fatality rate.
文摘Introduction: Hematological malignancies (HM) are relatively frequent nosological entities within the structure of morbidity by malignant tumors, exhibiting a severe evolution, restrained prognosis and negative socio-economic impact in the advanced stages and phases. Objective: The objective of the study was to identify the epidemiological patterns, and to evaluate the epidemiological trends and disease burden issues of HM in the Republic of Moldova and worldwide. Materials and Methods: The following research methods were used: epidemiological, descriptive statistics, clinico-analytic. The diagnosis was proved in all cases by histopathological, cytological, cytogenetic, molecular and immunophenotyping examinations. The qualitative type researches were performed and enriched by the narrative synthesis of the data. From the specialized international bibliographic sources and official statistics concerning HM. The narrative review of the reference sources was fulfilled in the form of a synthesis. Results: The number of newly diagnosed and followed-up patients with HM at the Institute of Oncology in 2016, 2017, 2018, 2019, 2020 and 2021 amounted respectively to 725, 802, 613, 628, 536 and 528, the incidence (new cases per 100,000 population) being 17.6, 19.5, 14.9, 17.7, 15.1 and 20.3. In 2021 HM constituted 6.2% of all newly-diagnosed cases with malignant tumors in the Republic of Moldova. In the same year Hodgkin lymphoma was diagnosed in 10.04% of cases, non-Hodgkin’s lymphomas—in 31.63%, multiple myeloma and plasma cells neoplasms—in 7.77%, lymphoid leukemias—in 17.42%, myeloid leukemias—in 12.31%, monocytic leukemias—in 0.95%, and other leukemias—in 16.29%. In 2019 the male rate was 51.5%, and the female rate—48.5%. Within 2 years males were 266 (50.4%), females—262 (49.6%). The age of 50 - 79 years prevailed in both genders (males—65%, females—72.5%). The children constituted 4.0% of the newly diagnosed cases, 4.8% of those under the follow-up at the end of the year 2019 and 6.4% of the newly diagnosed cases in 2021. The disease span from the onset to diagnosis ranged between 1 - 24 months and constituted on average 5.63 months, without a significant difference as compared to 2019 (5.76 months). The incidence of HM in Western countries is 14 - 19 new cases per 100,000 population (4% of all cases with malignant tumors). The incidence of non-Hodgkin’s lymphomas increased by 45% between 2006 and 2016, from 319,078 to 461,000 cases. Between 2006 and 2016, the incidence of leukemias increased by 26%, from 37,000,000 to 467,000 cases. Conclusions: The epidemiological study revealed slightly lower morbidity by HM in the Republic of Moldova as compared to the West European countries mainly due to the migration of a workable population. The patients with malignant lymphomas, male gender and age categories of 50 - 79 years proved to be commonly registered epidemiological patterns. The narrative analysis of the literature revealed that patients with HM may experience a considerable disease burden with a negative impact on their employment status, working productivity and annual household income.
文摘There were only 75 confirmed cases of coronavirus disease 2019(COVID-19)reported in Libya by the National Center for Disease Control during the first two months following the first confirmed case on 24 March 2020.However,there was dramatic increase in positive cases from June to now;as of 19 November 2020,approximately 357940 samples have been tested by reverse transcription polymerase chain reaction,and the results have revealed a total number of 76808 confirmed cases,47587 recovered cases and 1068 deaths.The case fatality ratio was estimated to be 1.40%,and the mortality rate was estimated to be 15.90 in 100000 people.The epidemiological situation markedly changed from mid-July to the beginning of August,and the country proceeded to the cluster phase.COVID-19 has spread in almost all Libyan cities,and this reflects the high transmission rate of the virus at the regional level with the highest positivity rates,at an average of 14.54%.Apparently,there is an underestimation of the actual number of COVID-19 cases due to the low testing capacity.Consequently,the Libyan health authority needs to initiate a large-scale case-screening process and enforce testing capacities and contact testing within the time frame,which is not an easy task.Advisably,the Libyan health authority should improve the public health capacities and conduct strict hygienic measures among the societies and vaccinate as many people against COVID-19 to minimize both the case fatality ratio and socio-economic impacts of the pandemic in Libya.
